The role of endothelin in connective tissue diseases

Rheumatology

Volumn 45, Issue SUPPL. 3, 2006, Pages

  Sticherling, Michael ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; SERPENTINE; SILDENAFIL;

ARTICLE; BLOOD VESSEL TONE; CELL TYPE; CONNECTIVE TISSUE DISEASE; CORRELATION ANALYSIS; DISEASE ACTIVITY; FIBROSIS; HEMODYNAMIC PARAMETERS; HUMAN; IDIOPATHIC DISEASE; INFLAMMATION; MITOGENESIS; NONHUMAN; PATHOGENESIS; PLEIOTROPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RHEUMATIC DISEASE; SKIN ULCER; SYSTEMIC SCLEROSIS; TISSUE LEVEL; TISSUE SPECIFICITY; ULCER HEALING; VASCULAR DISEASE;

CARDIOVASCULAR SYSTEM; CONNECTIVE TISSUE DISEASES; ENDOTHELIN-1; HUMANS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B;

EID: 33748992287     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel294     Document Type: Article

References (14)

1. Kahaleh MB. Vascular involvement in systemic sclerosis (SSc). Clin Exp Rheumatol 2004;2:S19-23.
2. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
3. Masaki T. Historical review: Endothelin. Trends Pharmacol Sci 2004;25:219-24.
4. Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003;48:1190-9.
5. Browatzki M, Pfeiffer CA, Schmidt J, Kranzhofer R. Endothelin-1 induces CD40 but not IL-6 in human monocytes via the proinflammatory transcription factor NF-kappaB. Eur J Med Res 2005;10:197-201.
6. Biondi ML, Marasini B, Bassani C, Agastoni A. Increased plasma endothelin levels in patients with Raynaud's phenomenon. New Engl J Med 1991;324:1139-40.
7. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61:227-37.
8. Teder P, Noble PW. A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 2000;23:7-10.
9. Hocher B, Schwarz A, Fagan KA et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000;23:19-26.
10. Hosoda K, Nakao K, Tamura N et al. Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor. J Biol Chem 1992;267:18797-804.
11. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. New Engl J Med 2004;351:1425-36.
12. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: Endothelin receptor antagonism. Ann Rheum Dis 2004;63:1009-14.
13. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. New Engl J Med 2002;346:896-903.
14. Korn JH, Mayes M, Matucci Cerinic M et al. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.